MX350659B - Tableta que contiene hidrato de metansulfonato del acido 1-ciclopropil- 8 - (difluorometoxi) -7- [ (1r) -1-metil-2,3-dihidro-1h-isoindol-5-il] -4-oxo-1,4-dihidroquinolin- 3-carboxilico. - Google Patents

Tableta que contiene hidrato de metansulfonato del acido 1-ciclopropil- 8 - (difluorometoxi) -7- [ (1r) -1-metil-2,3-dihidro-1h-isoindol-5-il] -4-oxo-1,4-dihidroquinolin- 3-carboxilico.

Info

Publication number
MX350659B
MX350659B MX2014006378A MX2014006378A MX350659B MX 350659 B MX350659 B MX 350659B MX 2014006378 A MX2014006378 A MX 2014006378A MX 2014006378 A MX2014006378 A MX 2014006378A MX 350659 B MX350659 B MX 350659B
Authority
MX
Mexico
Prior art keywords
dihydroquinoline
isoindole
difluoromethoxy
cyclopropyl
dihydro
Prior art date
Application number
MX2014006378A
Other languages
English (en)
Other versions
MX2014006378A (es
Inventor
Kakuda Sahoe
Miyazaki Tsutomu
Okada Kotaro
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of MX2014006378A publication Critical patent/MX2014006378A/es
Publication of MX350659B publication Critical patent/MX350659B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

(1) Una tableta de conformidad con la presente invención tiene contenido en porcentaje de hidrato de metansulfonato del ácido 1-ciclopropil-8-(difluorometoxi)-7-[(1R)-1-metil-2,3-dihidro-1H-i soindol-5-ill-4-oxo-1,4-hidroquinolin-3-carboxílico de entre 80 a 97.5% en masa. (2) La tableta es más pequeña que las Tabletas Geninax de 200 mg comercialmente disponibles. (3) Como resultado, se mejora el apego al tratamiento. (4) la tableta se disuelve de manera excelente, y, (5) la tableta es excelente en dureza y la friabilidad. (6) Como resultado, la presente invención soporta el recubrimiento con película y transporte, y es útil como una tableta de hidrato de metansulfonato del compuesto A.
MX2014006378A 2011-11-30 2012-11-29 Tableta que contiene hidrato de metansulfonato del acido 1-ciclopropil- 8 - (difluorometoxi) -7- [ (1r) -1-metil-2,3-dihidro-1h-isoindol-5-il] -4-oxo-1,4-dihidroquinolin- 3-carboxilico. MX350659B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011261727 2011-11-30
PCT/JP2012/080887 WO2013081044A1 (ja) 2011-11-30 2012-11-29 １－シクロプロピル－８－（ジフルオロメトキシ）－７－［（１ｒ）－１－メチル－２，３－ジヒドロ－１ｈ－イソインドール－５－イル］－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸のメタンスルホン酸塩水和物含有錠剤

Publications (2)

Publication Number Publication Date
MX2014006378A MX2014006378A (es) 2014-10-13
MX350659B true MX350659B (es) 2017-09-13

Family

ID=48535494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006378A MX350659B (es) 2011-11-30 2012-11-29 Tableta que contiene hidrato de metansulfonato del acido 1-ciclopropil- 8 - (difluorometoxi) -7- [ (1r) -1-metil-2,3-dihidro-1h-isoindol-5-il] -4-oxo-1,4-dihidroquinolin- 3-carboxilico.

Country Status (10)

Country Link
JP (1) JP6117112B2 (es)
CN (2) CN109662952A (es)
BR (1) BR112014012994A2 (es)
MX (1) MX350659B (es)
MY (1) MY169750A (es)
PH (1) PH12014501224A1 (es)
RU (1) RU2633477C2 (es)
SG (1) SG11201402597WA (es)
WO (1) WO2013081044A1 (es)
ZA (1) ZA201403942B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201717949A (zh) * 2015-10-29 2017-06-01 日本臟器製藥股份有限公司 以非索非那定為有效成分之錠劑
WO2017188362A1 (ja) * 2016-04-27 2017-11-02 富山化学工業株式会社 トスフロキサシントシル酸塩、崩壊剤および酸性アミノ酸を含む錠剤
JP7058104B2 (ja) * 2017-10-19 2022-04-21 日本化薬株式会社 アプレピタントを有効成分とする医薬錠剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
JP4809978B2 (ja) * 1998-11-10 2011-11-09 バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト 製薬学的モキシフロキサシン調製物
JP4370050B2 (ja) * 2000-12-04 2009-11-25 大正製薬株式会社 クラリスロマイシン錠剤およびその製造法
DE60318384T2 (de) * 2003-03-19 2009-02-19 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Nicht-hygroskopische pharmazeutische Zusammensetzungen die nicht hydratisierte Quinolon-Carbonsäuren enthalten
JP4702763B2 (ja) * 2003-07-30 2011-06-15 塩野義製薬株式会社 結晶セルロースを含有する安定な錠剤
PE20060489A1 (es) * 2004-08-13 2006-06-19 Schering Plough Ltd Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticosteroide
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
FI20080353A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
FI20080352A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
JP2011068647A (ja) * 2009-08-31 2011-04-07 Kowa Co アスパラギン酸又はその塩含有固形製剤
JPWO2011059075A1 (ja) * 2009-11-13 2013-04-04 味の素株式会社 グルタミン酸およびアルギニンの高含有製剤

Also Published As

Publication number Publication date
ZA201403942B (en) 2015-08-26
CN104039322A (zh) 2014-09-10
RU2014126094A (ru) 2016-01-27
PH12014501224B1 (en) 2014-09-08
WO2013081044A1 (ja) 2013-06-06
CN109662952A (zh) 2019-04-23
JPWO2013081044A1 (ja) 2015-04-27
RU2633477C2 (ru) 2017-10-12
MX2014006378A (es) 2014-10-13
BR112014012994A2 (pt) 2017-06-13
SG11201402597WA (en) 2014-09-26
PH12014501224A1 (en) 2014-09-08
JP6117112B2 (ja) 2017-04-19
MY169750A (en) 2019-05-15

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
MX2019009176A (es) Formulaciones de etanercept estabilizadas con iones metalicos.
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
NZ705578A (en) Coated pharmaceutical composition containing regorafenib
MY183969A (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
PH12016501328B1 (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
EA201490149A1 (ru) Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения
WO2013112950A3 (en) Certain chemical entities, compositions, and methods
EA201691139A1 (ru) Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты и полиоксиэтиленовое касторовое масло
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX350659B (es) Tableta que contiene hidrato de metansulfonato del acido 1-ciclopropil- 8 - (difluorometoxi) -7- [ (1r) -1-metil-2,3-dihidro-1h-isoindol-5-il] -4-oxo-1,4-dihidroquinolin- 3-carboxilico.
PH12014502407B1 (en) New alfentanil composition for the treatment of acute pain
MY188302A (en) Solid pharmaceutical composition comprising amlodipine and losartan
MX343986B (es) Composiciones farmaceuticas estabilizadas que comprenden sales de rasagilina.
WO2013124832A3 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2011121475A3 (en) Modified release dosage form comprising desvenlafaxine or salts thereof
TH153154A (th) ยาเม็ดซึ่งมี 1-ไซโคลโพรพิล-8-(ไดฟลูออโรเมธอกซี)-7-[(1r)-1-เมธิล-2,3-ไดไฮโดร-1h-ไอโซอินโดล-5-อิล]-4-ออกโซ-1,4-ไดไฮโดรควิโนลีน-3-คาร์บอกซิลิคแอซิดมีเธนซัลโฟนิคแอซิดไฮเดรท
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
MX2012014342A (es) Preparacion de una sal de levalbuterol.
GR1007907B (el) Φαρμακευτικο σκευασμα περιεχον ενα φαινοκαρβαμικο αναστολεα της ακετυλχοληνεστερασης

Legal Events

Date Code Title Description
FG Grant or registration